Physician associates ‘should be banned from seeing patients without review'
The study suggests a major change to the role of PAs after it acknowledged they have been used as substitutes for doctors, despite having significantly less training.
More than 3,500 PAs and 100 anaesthesia associates (AAs) are working in the NHS and there have been previous calls for an expansion in their number.
But a general lack of support for the roles from the medical profession – plus high-profile deaths of patients who were misdiagnosed by PAs – led Health Secretary Wes Streeting to order a review.
Presenting her findings, Professor Gillian Leng, president of the Royal Society of Medicine, said: 'Crucially I'm recommending that PAs should not see undifferentiated or untriaged patients.
'If (patients) are triaged, they (PAs) should be able to see adult patients with minor ailments in line with relevant guidance from the Royal College of GPs.'
She said more detail was needed on which patients can be seen by PAs and national clinical protocols should be developed in this area.
She added: 'Let's be clear, (the role of PAs) is working well in some places, but there indeed has been some substitution and any substitution is clearly risky and confusing for patients.'
Prof Leng also recommended PAs should be renamed 'physician assistants' to position them 'as a supportive, complementary member of the medical team', while AAs should be renamed 'physician assistants in anaesthesia'.
Newly qualified PAs should also work in hospitals for two years before they are allowed to work in GP surgeries or mental health trusts.
The study said safety concerns in relation to PAs were 'almost always about making a diagnosis and deciding the initial treatment, particularly in primary care or the emergency department, where patients first present with new symptoms.'
It added: 'It is here that the risk of missing an unusual disease or condition is highest, and where the more extensive training of doctors across a breadth of specialties is important.
'Making the wrong initial diagnosis and putting patients on an inappropriate pathway can be catastrophic.'
Despite the shorter two years of training for PAs, where local NHS services have struggled with filling roles, 'the easy option in some cases was simply to fill gaps in medical rotas with PAs', the report went on.
'This seems to have been done without taking into account the more limited training of the PAs and how the roles would interact, other than with the caveat that they would be supervised by doctors.
'This lack of planning may have been responsible for driving the resentment felt by some resident (doctors) and potentially exposed patients to unnecessary risk.'
The study noted concerns in the medical profession about the impact on training and employment of resident doctors when PAs take on tasks.
When it comes to the safety of PAs and AAs, Prof Leng said the 'evidence is poor', with 'no compelling evidence' in published research 'that PAs were safe to work as doctor substitutes in primary care'.
She also said the evidence was poor when it came to cost effectiveness.
The report said that while research suggests patients are satisfied after seeing a PA, some did not know they were not seeing a doctor.
Many doctors also told the review they were concerned about the time required to supervise PAs and AAs and the lack of training for supervisors about the role of PAs.
A survey conducted for the report found 'relatively few doctors felt it was appropriate for PAs to diagnose illness', with only 29% of those working with PAs in primary care backing this, and 14% in secondary care.
The survey also found 'marked differences in which tasks were considered appropriate in primary and secondary care, with PAs significantly more likely than doctors to believe that certain activities were appropriate for them to carry out'.
When it came to AAs, there were also questions over whether the role was actually needed as fully qualified anaesthetists already face tough competition to find a job.
Prof Leng concluded there were 'no convincing reasons to abolish the roles of AA or PA' but there is also no case 'for continuing with the roles unchanged'.
She recommended that both PAs and AAs should have the opportunity for ongoing training and development, with potential to prescribe medicines in the future, and they should also should have the opportunity to become an 'advanced' PA or AA.
A named doctor should take overall responsibility for each PA, while clothing, lanyards, badges and staff information should be standardised to 'distinguish physician assistants from doctors'.
Six patient deaths linked to contact with PAs have been recorded by coroners in England.
One high-profile death involved Emily Chesterton, 30, who died from a pulmonary embolism. She was misdiagnosed by a PA on two occasions and told she had anxiety.
Unison head of health, Helga Pile, said: 'By working closely with doctors and other healthcare professionals, these roles can make a real difference to the improvement of services and reduction of waiting lists.
'Clearer identification of physician associates and anaesthesia associates will give patients a greater understanding of who's delivering their care and what they can expect. '
Dr Tom Dolphin, chair of BMA council, said the review 'laid bare the catastrophic failures in NHS leadership that have put patients at serious risk of harm' but said its recommendations 'do not adequately protect patients'.
He added: 'Despite correctly recommending that assistants shouldn't be the first person seeing patients coming straight through the doors in GP practices or in A&E, the report then contradicts itself by saying that PAs can act as a first point of contact in primary care for minor and common conditions.
'It is not clear how these two recommendations can coexist, and this must be urgently clarified. Minor complaints are only minor in retrospect and serious conditions can present in subtle or unusual ways.
'No doubt doctors will look back at this report as a moment when historic failures could have been addressed and patients finally protected – but sadly will see this as an inadequate response to what is a patient safety scandal.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO, bringing over 25 years' experience in oncology drug development and clinical and regulatory strategy Carolyn Edwards, PhD appointed VP, R&D, with over 15 years' expertise in drug development and strategic partnering Edinburgh, UK, 18 July 2025 - Trogenix Ltd ('Trogenix'), a pioneering biotech company dedicated to developing innovative cancer therapies, today announces two senior appointments as the Company advances its pipeline towards the clinic. Atif Abbas, MD joins as Chief Medical Officer (CMO), bringing over 25 years of pharmaceutical and biotechnology leadership with extensive experience guiding drug development programmes from preclinical stages through clinical trials to market approval and will drive clinical excellence through to commercialisation. Carolyn Edwards, PhD joins as Vice President (VP), R&D, bringing over 15 years of comprehensive experience in drug development and strategic partnerships and will focus on accelerating Trogenix's R&D pipeline. Ken Macnamara, Chief Executive Officer at Trogenix, added: 'As we enter the clinical phase, we are delighted to welcome Atif as CMO and Carolyn as VP, R&D at this transformative moment for Trogenix. Atif's deep expertise in clinical strategy, innovative trial designs, and track record of bringing advanced therapies to patients, combined with Carolyn's experience across immunology, translational science, and programme strategy, significantly bolsters our capabilities as we advance the Odysseus platform. The appointment of these highly talented experts will be instrumental as we advance our pipeline of immuno-oncology assets through the clinic.' An oncology-focused physician, Atif has successfully led numerous first-in-human IND submissions for immunotherapy compounds, including PDL1-41bb bispecific antibodies, NKG2A antibodies, and STING agonists, while playing pivotal roles in high-profile regulatory submissions such as the successful BLA filing for avelumab in Merkel cell carcinoma. Most recently serving as VP and Head of Immuno-oncology at Servier Pharma, he has built and led multidisciplinary clinical development teams across senior roles at Spring Bank Pharma, Kadmon (acquired by Sanofi for $1.9B in 2021), Merck and AbbVie. Atif earned his medical degree from King Edward Medical University in Lahore, Pakistan, completed oncology training at Mayo Hospital, and pursued clinical research at Yale-Griffin Hospital in the U.S. He is a graduate of the Global Clinical Scholars Research Programme at Harvard Medical School and a widely published author in oncology and medical safety. Atif Abbas, newly appointed Chief Medical Officer at Trogenix, said: 'Having spent over two decades navigating the complexities of oncology drug development — from first-in-human studies to successful market approvals — I'm excited to join Trogenix to chart our course through the clinic. The innovation driven by the Odysseus platform enabling a 'Trojan horse' approach for potential curative responses to aggressive cancers offers significant hope and I look forward to accelerating our clinical programmes and bringing these therapies to the patients who need them most.' Carolyn brings a unique blend of scientific insight, operational leadership, and partnership-building expertise that will be invaluable in the expansion and acceleration of Trogenix's R&D pipeline. Her proven track record includes progressing immunotherapies from concept to candidate, securing a clinical development partnership and asset transfer. Carolyn completed her PhD at the Department of Immunology, Imperial College London, UK, continuing her research at University College London before Translational Science and R&D Leadership positions in immuno-oncology at Crescendo Biologics and Achilles Therapeutics. Carolyn Edwards, newly appointed VP, R&D, commented: 'I'm thrilled to join Trogenix and contribute to maximising the potential of the Odysseus platform through its next phase of development. Having guided multiple oncology programmes from discovery and clinical stages, I look forward to applying this experience to help accelerate the Company's innovative pipeline.' -ends- About Trogenix Trogenix unites cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach through its Odysseus platform. Using proven AAV vectors, our proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumour cells without detection. Our SSEs enable unprecedented precision in gene control, effectively revealing cancer to the body's immune system and killing tumour cells. For any cells escaping Trogenix's technology, our 'Trojan horse' can counter recurrence, offering potentially curative 'one-and-done' treatments for aggressive tumours. With our lead asset showing curative potential in preclinical glioblastoma studies, we're poised to transform treatment paradigms across multiple cancer types and explore applications beyond oncology, such as regenerative medicine. For more information, visit For more information, please contact: Trogenix Ltd. info@ Media and Investor Enquiries: trogenix@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Androgen Excess? New Guidelines Shift Focus Beyond Just PCOS
The Society for Endocrinology, a UK-based organization representing a global community of scientists and clinicians working with hormones, has published updated guidelines for diagnosing and managing androgen excess in women. The new recommendations provide a practical, evidence-based framework, emphasizing early identification and treatment tailored to the underlying etiology. Unlike some national protocols that focus primarily on polycystic ovary syndrome (PCOS) — the most common cause of hyperandrogenism — these guidelines cover a broader spectrum of causes, offering a more comprehensive clinical approach. Early detection remains crucial, as certain effects of androgen excess — such as voice deepening, clitoromegaly, and androgenic alopecia — may be irreversible if left untreated. The guidelines define total testosterone levels above 86 ng/dL or free testosterone levels above 3.2 ng/dL as suggestive of hyperandrogenism. They also highlighted the importance of using accurate and standardized testing methods, cautioning that both under- and overdiagnosis can result from laboratory variability. To improve diagnostic reliability, the Society for Endocrinology recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) over immunoassays, citing its superior specificity and sensitivity, particularly at the low hormone concentrations typically observed in women. Proper sample preparation is also critical. Recommendations include fasting for at least 8 hours, collecting blood samples in the early morning between days 3 and 5 of the menstrual cycle, and discontinuing hormonal contraceptives for 6 to 8 weeks prior to testing. Given the high variability between labs, Karen de Marca Seidel, MD, director of the Brazilian Society of Endocrinology and Metabolism, highlighted the importance of this preparation in an interview with Medscape's Portuguese edition. Speaking to Medscape's Portuguese edition , Elaine Frade, PhD, head of the Department of Female Endocrinology, Andrology, and Transgender Health at the Brazilian Society of Endocrinology and Metabolism, noted that while LC-MS/MS is the gold standard, its availability is still limited in many countries, including Brazil, due to high costs and limited insurance coverage. As a result, many laboratories only offer LC-MS/MS testing after a preliminary abnormal result on conventional immunoassays. Causes and Treatment 'The etiological investigation should be prompt and accurate, as treatment depends on the underlying cause. Symptoms can also have a significant psychosocial impact and may, in some cases, leave permanent effects,' Frade said. Androgen excess in women may stem from a range of causes — most commonly ovarian or adrenal in origin, but also from exogenous androgen use or, more rarely, disorders of sexual development. Ovarian causes include PCOS, ovarian hyperthecosis, and androgen-secreting tumors. Adrenal causes include congenital adrenal hyperplasia and adrenal tumors. Given its high global prevalence, PCOS should be the initial diagnostic consideration. According to the widely accepted Rotterdam criteria, diagnosis requires at least two of the following: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism, and polycystic ovarian morphology on ultrasound. Frade noted that many women with PCOS also present with overweight or obesity and varying degrees of insulin resistance. Treatment for PCOS generally involves both pharmacologic and lifestyle interventions. These may include combined oral contraceptives, weight reduction, and regular physical activity. In cases where symptoms persist, antiandrogens may be introduced. 'The choice of contraceptive depends on the predominant symptoms and the patient's individual response. A progestin can be selected based on its targeted effect,' Frade explained. Seidel noted that in Brazil, commonly used therapeutic agents include spironolactone, metformin, and cyproterone acetate. The latter, a synthetic progestin with antiandrogenic properties, is not widely available in all countries but remains an option in selected cases. Ovarian hyperthecosis, characterized by diffuse hyperplasia of the theca cells leading to sustained androgen production, is more frequently diagnosed in postmenopausal women. In such cases, bilateral oophorectomy is often the preferred management. For younger patients, conservative treatment using oral contraceptives and antiandrogens may be a viable option. Androgen-secreting ovarian tumors should be considered in cases with abrupt symptom onset, rapid progression, and pronounced signs of virilization, such as increased muscle mass and voice deepening. In these patients, serum testosterone levels often exceed 5 nmol/L, and transvaginal ultrasound is warranted for further evaluation. Among adrenal causes, nonclassic congenital adrenal hyperplasia is particularly noteworthy. Estimated to affect approximately 1% of women, this genetic condition can present with subtle symptoms and minimal virilization. A thorough family history should be taken. Screening includes measuring 17-hydroxyprogesterone during the follicular phase, with adrenocorticotropic hormone stimulation testing in ambiguous cases. Low-dose glucocorticoid therapy is typically reserved for symptomatic women seeking pregnancy or those who do not respond adequately to hormonal contraceptives. Adrenal tumors that produce androgens usually lead to elevated dehydroepiandrosterone sulfate levels. Diagnostic workup should include imaging studies such as abdominal CT or MRI. Treatment is surgical, with mitotane or chemotherapy considered in malignant cases. Seidel acknowledged that diagnosis is not always straightforward. 'In major hospitals or referral centers, comprehensive investigations are feasible. But in the private sector, the quality of the workup often depends on the physician's expertise and the patient's ability to access additional testing,' she said. When clinical findings do not align with classic etiologies of hyperandrogenism, exogenous androgen use must be considered — even if patients do not readily disclose it. According to Seidel, this may now be one of the most common, yet underrecognized, causes of androgen excess in women in Brazil. Potential sources include hormone implants containing testosterone or gestrinone, anabolic steroids used for aesthetic purposes, or off-label hormone replacement therapies during menopause. Due to limited regulation and scarce reliable information about these products, many patients are unaware they are being exposed to androgens. Seidel noted that many present with clinical signs of androgen excess without realizing they are taking androgens. In this context, Frade emphasized a critical point: 'There is no minimum testosterone threshold below which hormone replacement is indicated in women.' She stressed that the concept of 'female androgen deficiency' lacks strong scientific validation and should not be used to justify hormone supplementation. Frade also highlighted that managing hyperandrogenism can be complex. Treatment typically requires long-term follow-up, and patients may have unrealistic expectations regarding the reversal of physical signs. 'It's essential to establish a clear and realistic treatment plan from the start. Even with effective management of the underlying cause, some clinical manifestations may be permanent or show only limited improvement,' she said.


Medscape
an hour ago
- Medscape
NICE Widens Access to Ribociclib for Early Breast Cancer
The National Institute for Health and Care Excellence (NICE) has recommended ribociclib (Kisqali, Novartis) for routine NHS use in adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer in patients at high risk of recurrence. The drug is now recommended for use alongside an aromatase inhibitor after initial treatments, such as surgery. In pre-menopausal women, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone agonist. Targeted Therapy for Common Breast Cancer Subtype Ribociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by blocking proteins that drive cancer cell growth and division. NICE said the treatment 'represents a significant advance' in managing hormone receptor-positive, HER2-negative early breast cancer. Breast cancer is the most common cancer in the UK. Hormone receptor-positive, HER2-negative breast cancer is the most common subtype, accounting for about 68% of all UK cases. Expanded NHS Use Follows Evidence Submission Until now, NHS access in England was limited to patients whose cancer had spread to nearby lymph nodes. NICE approved this use of ribociclib in April 2025 but asked Novartis for more evidence to justify broader access. Following further review, NICE concluded in final draft guidance that ribociclib with an aromatase inhibitor offers clinical benefit and value for money. It is now considered a cost-effective use of NHS resources. Trial Shows Delayed Recurrence A clinical trial involving more than 5000 patients showed that ribociclib combined with an aromatase inhibitor delayed disease recurrence compared with the aromatase inhibitor alone. The latest analysis, based on a mean of 33 months' follow-up, continued to show improved invasive disease-free survival across key subgroups. However, NICE said that it remained unclear whether the combination increased overall survival and that more mature data, including predictions of longer-term outcomes, is needed. Further data from the trial are expected in May 2026. Comparable to Other Options Indirect evidence suggests that ribociclib plus an aromatase inhibitor is as effective as abemaciclib plus endocrine therapy. Abemaciclib is currently used for node-positive breast cancer. Ribociclib in combination with fulvestrant is already recommended for treating hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy. This demonstrated 'the drug's versatility across different stages of the disease,', NICE said. Helen Knight, director of medicines evaluation at NICE, described the latest decision as 'fantastic news for the tens of thousands of patients and their loved ones'. An estimated 5700 people with early breast cancer could benefit from expanded access to the combination treatment. Relapse after initial treatment occurs in about 30% of people with early breast cancer. Patient experts told the NICE committee that the high risk of recurrence has a considerable impact on quality of life. 'The fear of the cancer returning is a common cause of stress and anxiety for people and their families, affecting physical and psychological wellbeing,' they said. Treatment options are limited and have unpleasant side effects. Having different options is particularly important because people often choose treatments based on their side-effect profiles. Both patient and clinical experts emphasised the importance of treatment choice. Dosage, Side Effects, and Pricing Ribociclib is taken orally, which may improve convenience and adherence compared with alternatives. The usual dose of ribociclib is: 400 mg once daily (two 200 mg tablets) for primary breast cancer 600 mg once daily (three 200 mg tablets) for locally advanced or secondary disease Common side effects include leukopaenia and increased infection risks, anaemia, anorexia, nausea and vomiting, diarrhoea and constipation, abdominal pain, fatigue, sore mouth, shortness of breath, cough, rashes, and hair loss. The list prices of ribociclib 200-mg tablets are: £983.33 for 21 tablets £1966.67 for 42 tablets £2950.00 for 63 tablets A simple patient access scheme allows the NHS to purchase the drug at a confidential discount. Knight said the expanded access was 'also due in no small part to the willingness of companies to engage with us constructively, as in the case with ribociclib, to ensure the benefits of their treatments are properly presented and appropriately priced'.